Guardant Health, Inc. (NASDAQ:GH) Shares Purchased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC boosted its position in Guardant Health, Inc. (NASDAQ:GH) by 108.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,026 shares of the company’s stock after buying an additional 41,059 shares during the quarter. Knights of Columbus Asset Advisors LLC owned 0.07% of Guardant Health worth $2,138,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Guardant Health by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,950,230 shares of the company’s stock worth $324,565,000 after purchasing an additional 146,902 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Guardant Health by 2.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 568,148 shares of the company’s stock worth $16,840,000 after purchasing an additional 16,111 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Guardant Health in the 3rd quarter worth about $1,689,000. Rhumbline Advisers increased its position in shares of Guardant Health by 5.8% in the 3rd quarter. Rhumbline Advisers now owns 159,660 shares of the company’s stock worth $4,732,000 after purchasing an additional 8,688 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Guardant Health by 31.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,211,499 shares of the company’s stock worth $35,909,000 after purchasing an additional 292,888 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on GH shares. JPMorgan Chase & Co. dropped their target price on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Canaccord Genuity Group lowered their price objective on shares of Guardant Health from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, February 23rd. Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a research report on Friday, April 5th. The Goldman Sachs Group lowered their price objective on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, April 15th. Finally, Piper Sandler lowered their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, February 26th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Guardant Health presently has an average rating of “Moderate Buy” and a consensus price target of $40.40.

Insiders Place Their Bets

In related news, insider Kumud Kalia purchased 2,187 shares of Guardant Health stock in a transaction dated Monday, March 18th. The stock was bought at an average cost of $17.82 per share, with a total value of $38,972.34. Following the purchase, the insider now owns 12,722 shares in the company, valued at approximately $226,706.04. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 6.20% of the stock is owned by insiders.

Guardant Health Stock Performance

NASDAQ GH opened at $16.07 on Friday. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $41.06. The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The company has a 50-day moving average price of $19.21 and a two-hundred day moving average price of $23.23.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.65). Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. The firm had revenue of $155.05 million during the quarter, compared to the consensus estimate of $151.71 million. Sell-side analysts expect that Guardant Health, Inc. will post -3.49 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.